GENinCode
GENI · AIM · Health Care · mcap £4.7m · 0.6p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Holding | Holding(s) in Company | |
| 29 Sep 26 | Results | Half-year Results
H1 2026 revenues fell to £1.1m from £1.6m; FDA De Novo submission expected November 2026; cash runway to Q1 2027. |
−20.0% |
| 22 Sep 26 | Routine | Notice of Results | |
| 28 Aug 26 | Results | CARDIO inCode-Score milestone clinical results
CARDIO inCode-Score genetic test shows positive real-world clinical results for coronary artery disease prevention. |
+10.5% |
| 01 Jul 26 | Routine | Result of AGM | |
| 11 Jun 26 | Holding | Holding(s) in Company | |
| 10 Jun 26 | Holding | Holding(s) in Company | |
| 08 Jun 26 | Results | Final Results
FY25 revenues up 14% to £3.1m; FDA De Novo submission expected Q3 2026; Thermo Fisher collaboration progressing. |
−13.0% |
| 04 Jun 26 | Holding | Holding(s) in Company | |
| 03 Jun 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Routine | Notice of Results | |
| 08 May 26 | Holding | Holding(s) in Company | |
| 07 May 26 | Director dealing | Grant of Share Options & PDMR Dealings
Grant of Share Options, Surrender of Existing Options & PDMR Dealings |
−14.3% |
| 15 Apr 26 | Holding | Holding(s) in Company | |
| 14 Apr 26 | Holding | Holding(s) in Company | |
| 26 Feb 26 | Holding | Holding(s) in Company | |
| 24 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 09 Feb 26 | Director dealing | Result of GM, Director Shareholdings and TVR
Result of General Meeting, Director Shareholdings and Total Voting Rights |
+0.0% |
| 06 Feb 26 | Fundraise | Additional Subscription
Additional share subscription of £580,000 raises total gross proceeds to approximately £4.7 million. |
+0.0% |
| 26 Jan 26 | Fundraise | Result of Retail Offer
Retail offer closed, raising £0.2m through issue of 20m shares at 1p each. |
−4.5% |
| 22 Jan 26 | Fundraise | Result of Placing and Subscription
GENinCode raises £3.9m gross through placing and subscription at 1p per share. |
−37.8% |
| 21 Jan 26 | Fundraise | Retail Offer
GENinCode launches retail offer for up to £500,000 and placing for minimum £3.5 million at 1 pence per share. |
−2.6% |
| 21 Jan 26 | Fundraise | Placing and Subscription
GENinCode raises minimum £3.5m through placing and subscription at 1p per share, with retail offer of up to £0.5m. |
−2.6% |
| 17 Dec 25 | Collaboration with Sohin Genetics
GENinCode signs distribution agreement with Sohin Genetics to sell CARDIO inCode-Score test in Mexico. |
−1.8% | |
| 08 Dec 25 | Holding | Holding(s) in Company | |
| 04 Dec 25 | Collaboration with Thermo Fisher
GENinCode partners with Thermo Fisher to commercialise CARDIO inCode-Score genetic risk test in US and EMEA. |
+30.0% | |
| 03 Dec 25 | Approval of CARDIO inCode-score in New York state
New York State approves CARDIO inCode-score test for heart disease risk prediction with CMS reimbursement. |
+39.5% | |
| 27 Oct 25 | Publication of Landmark Study in JACC: Advances
Kaiser Permanente study published in JACC: Advances validates CARDIO inCode-Score for coronary heart disease risk prediction. |
+1.6% | |
| 13 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.